Bank of America
ENSC icon

Bank of America’s Ensysce Biosciences ENSC Stock Holding History

Bank of America’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-72
Closed -$66 – 6077
2025
Q4 		$66 Buy
72
+48
+200% +$89 ﹤0.01% 6909
2025
Q3 		$57 Buy
24
+5
+26% +$11 ﹤0.01% 7979
2025
Q2 		$42 Buy
19
+11
+138% +$25 ﹤0.01% 8137
2025
Q1 		$20 Hold
8
– – ﹤0.01% 8136
2024
Q4 		$65 Buy
8
+3
+60% +$21 ﹤0.01% 7823
2024
Q3 		$17 Buy
5
+1
+25% +$6 ﹤0.01% 7987
2024
Q2 		$31 Buy
+4
New +$36 ﹤0.01% 7926
2023
Q4 		– Sell
-4
Closed -$81 – 8048
2023
Q3 		$81 Buy
+4
New +$114 ﹤0.01% 7477
2023
Q1 		– Sell
-34
Closed -$4.54K – 7923
2022
Q4 		$4.54K Buy
+34
New +$16.1K ﹤0.01% 7072
2022
Q1 		– Hold
0
– – – 8384
2021
Q4 		– Hold
0
– – – 8323

Other funds holding ENSC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bank of America's ENSC Position: Q1 2026 in Review

Bank of America sold out of Ensysce Biosciences (ENSC) in Q1 2026, closing a stake of 72 shares — an estimated $66 sold.

Bank of America first reported a position in ENSC in Q4 2022 and held it in 9 quarters. The position peaked at $4.54K in Q4 2022. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2026.

  • Bank of America reported no remaining Ensysce Biosciences position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 72 Ensysce Biosciences shares in Q1 2026, an estimated $66.
  • Bank of America first reported a position in Ensysce Biosciences in Q4 2022 and held it in 9 quarters.
  • Bank of America's Ensysce Biosciences position peaked at $4.54K in Q4 2022.
  • 15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.